Fennec Pharmaceuticals Inc FENC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Trading Information
- Previous Close Price
- $11.62
- Day Range
- $11.77–12.88
- 52-Week Range
- $5.65–13.25
- Bid/Ask
- $10.00 / $13.27
- Shares Outstanding
- 35.31M
- Market Cap
- $450.49M
- Volume/Avg
- 132 / 195,732
Key Statistics
- Price/Earnings (Normalized)
- 54.91
- Price/Sales
- 6.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 35
- Website
- https://www.fennecpharma.com
Valuation
Metric | FENC |
|---|---|
Price/Earnings (Normalized) | 54.91 |
Price/Book Value | 8.32 |
Price/Sales | 6.18 |
Price/Cash Flow | 37.21 |
Price/Earnings
FENC
Financial Strength
Metric | FENC |
|---|---|
Quick Ratio | 5.47 |
Current Ratio | 6.11 |
Interest Coverage | 5.18 |
Quick Ratio
FENC
Profitability
Metric | FENC |
|---|---|
Return on Assets (Normalized) | 12.89% |
Return on Equity (Normalized) | 28.22% |
Return on Invested Capital (Normalized) | 23.25% |
Return on Assets
FENC
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|D%<w^m | LOCK|$?Ch | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<w?TDV | LOCK|<Q^< | $99B | |||
| Moderna Inc MRNA | LOCK|v<F@K& | LOCK|H$ | $87B | |||
| argenx SE ADR ARGX | LOCK|?Dn@<@ | LOCK|bj | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|sdGk&v% | LOCK|&Rn | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|<&rCcmX | LOCK|X!>R< | $31B | |||
| Incyte Corp INCY | LOCK|chPTt?Q | LOCK|^G | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>M%zCC | LOCK|G!yR | $21B | |||
| BioNTech SE ADR BNTX | LOCK|Km&#bb | LOCK|!P | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|BV>b%d | LOCK|&H | $15B |